Trial Profile
First-line carboplatin + docetaxel + bevacizumab then bevacizumab in patients with stage IV NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2014 New trial record